Correction to: Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study

被引：0
|
作者：
Emmanuelle Kuhn
Philippe Caron
Brigitte Delemer
Isabelle Raingeard
Hervé Lefebvre
Gérald Raverot
Christine Cortet-Rudelli
Rachel Desailloud
Clementine Geffroy
Robin Henocque
Yves Brault
Thierry Brue
Philippe Chanson
机构：
[1] Centre de Référence des Maladies Rares de l’Hypophyse HYPO,Assistance Publique
[2] Université Paris-Saclay (Université Paris-Sud),Hôpitaux de Paris, Hôpital Bicêtre
[3] Inserm,undefined
[4] Signalisation Hormonale,undefined
[5] Physiopathologie Endocrinienne et Métabolique,undefined
[6] CHU de Toulouse,undefined
[7] Hôpital Larrey,undefined
[8] 24 Chemin de Pouvourville,undefined
[9] TSA 30030,undefined
[10] CHU de Reims—Hôpital Robert Debré,undefined
[11] Avenue du Général Koenig,undefined
[12] CHRU de Montpellier,undefined
[13] Maladies Endocriniennes,undefined
[14] Hopital Lapeyronie,undefined
[15] CHU de Rouen,undefined
[16] Hospices civils de Lyon,undefined
[17] Hôpital Louis Pradel,undefined
[18] CHR Lille,undefined
[19] Hôpital Claude Huriez,undefined
[20] Rue Michel Polonovski,undefined
[21] CHU d’Amiens,undefined
[22] Hôpital Nord,undefined
[23] Place Victor Pauchet,undefined
[24] Pfizer France,undefined
[25] CHU de Marseille,undefined
[26] Hôpital de la Conception,undefined
来源：
Endocrine | 2021年 / 71卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
引用
收藏
页码：265 / 265
相关论文
共 41 条
  • [1] Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
    Emmanuelle Kuhn
    Philippe Caron
    Brigitte Delemer
    Isabelle Raingeard
    Hervé Lefebvre
    Gérald Raverot
    Christine Cortet-Rudelli
    Rachel Desailloud
    Clementine Geffroy
    Robin Henocque
    Yves Brault
    Thierry Brue
    Philippe Chanson
    Endocrine, 2021, 71 : 158 - 167
  • [2] Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study (September, 10.1007/s12020-020-02501-3, 2020)
    Kuhn, Emmanuelle
    Caron, Philippe
    Delemer, Brigitte
    Raingeard, Isabelle
    Lefebvre, Herve
    Raverot, Gerald
    Cortet-Rudelli, Christine
    Desailloud, Rachel
    Geffroy, Clementine
    Henocque, Robin
    Brault, Yves
    Brue, Thierry
    Chanson, Philippe
    ENDOCRINE, 2021, 71 (01) : 265 - 265
  • [3] Pegvisomant treatment in patients with acromegaly in clinical practice: The French ACROSTUDY
    Chanson, Philippe
    Brue, Thierry
    Delemer, Brigitte
    Caron, Philippe
    Borson-Chazot, Francoise
    Zouater, Hichem
    ANNALES D ENDOCRINOLOGIE, 2015, 76 (06) : 664 - 670
  • [4] Pegvisomant treatment in acromegaly in clinical practice: Final results of the French ACROSTUDY (312 patients)
    Barraud, Sara
    Caron, Philippe
    Raingeard, Isabelle
    Lefebvre, Herve
    Raverot, Gerald
    Cortet-Rudelli, Christine
    Desailloud, Rachel
    Henocque, Robin
    Brault, Yves
    Brue, Thierry
    Chanson, Philippe
    Delemer, Brigitte
    ANNALES D ENDOCRINOLOGIE, 2021, 82 (06) : 582 - 589
  • [5] Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
    Neggers, Sebastian J. C. M. M.
    de Herder, Wouter W.
    Feelders, Richard A.
    van der Lely, A. J.
    PITUITARY, 2011, 14 (03) : 253 - 258
  • [6] Factors associated with disease control failure in acromegaly patients treated with pegvisomant: an ACROSTUDY analysis
    Giampietro, Antonella
    Chiloiro, Sabrina
    Urbani, Claudio
    Pivonello, Rosario
    Carlsson, Martin Ove
    Dassie, Francesca
    Prencipe, Nunzia
    Ragonese, Marta
    Gomez, Roy
    Granato, Simona
    Cannavo, Salvatore
    Grottoli, Silvia
    Maffei, Pietro
    Colao, Annamaria
    Bogazzi, Fausto
    Bianchi, Antonio
    ENDOCRINE CONNECTIONS, 2024, 13 (03)
  • [7] Correction to: Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly
    Sabrina Chiloiro
    Gherardo Mazziotti
    Antonella Giampietro
    Antonio Bianchi
    Stefano Frara
    Marilda Mormando
    Alfredo Pontecorvi
    Andrea Giustina
    Laura De Marinis
    Pituitary, 2018, 21 : 309 - 309
  • [8] A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly
    Trainer, Peter J.
    Ezzat, Shereen
    D'Souza, Gwyn A.
    Layton, Gary
    Strasburger, Christian J.
    CLINICAL ENDOCRINOLOGY, 2009, 71 (04) : 549 - 557
  • [9] Long-Term Efficacy and Safety of Pegvisomant in Combination With Long-Acting Somatostatin Analogs in Acromegaly
    Neggers, S. J. C. M. M.
    Franck, S. E.
    de Rooij, F. W. M.
    Dallenga, A. H. G.
    Poublon, R. M. L.
    Feelders, R. A.
    Janssen, J. A. M. J. L.
    Buchfelder, M.
    Hofland, L. J.
    Jorgensen, J. O. L.
    van der Lely, A. J.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (10): : 3644 - 3652
  • [10] Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone
    van der Lely, Aart-Jan
    Bernabeu, Ignacio
    Cap, Jan
    Caron, Philippe
    Colao, Annamaria
    Marek, Josef
    Neggers, Sebastian
    Birman, Pascal
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2011, 164 (03) : 325 - 333
12345